Allogene Therapeutics, Inc. (NASDAQ:ALLO) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Shares of Allogene Therapeutics, Inc. (NASDAQ:ALLO) have been given an average rating of “Moderate Buy” by the eleven analysts that are presently covering the firm, MarketBeat.com reports. One analyst has rated the stock with a sell rating, two have issued a hold rating and eight have issued a buy rating on the company. The average 12-month price target among brokerages that have covered the stock in the last year is $15.35.

A number of equities research analysts have recently weighed in on the company. HC Wainwright lowered their target price on Allogene Therapeutics from $23.00 to $12.00 and set a “buy” rating for the company in a research note on Wednesday, November 15th. JPMorgan Chase & Co. lowered their price objective on Allogene Therapeutics from $11.00 to $9.00 and set an “overweight” rating for the company in a research report on Monday, September 25th. Finally, Oppenheimer reiterated an “outperform” rating and set a $28.00 price target on shares of Allogene Therapeutics in a report on Thursday, August 3rd.

Hedge Funds Weigh In On Allogene Therapeutics

A number of institutional investors have recently added to or reduced their stakes in the company. Great West Life Assurance Co. Can raised its holdings in Allogene Therapeutics by 26.1% in the first quarter. Great West Life Assurance Co. Can now owns 8,827 shares of the company’s stock worth $43,000 after purchasing an additional 1,826 shares in the last quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. increased its stake in shares of Allogene Therapeutics by 1.2% in the 1st quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 165,378 shares of the company’s stock worth $817,000 after acquiring an additional 1,933 shares in the last quarter. Ensign Peak Advisors Inc increased its stake in shares of Allogene Therapeutics by 11.3% during the third quarter. Ensign Peak Advisors Inc now owns 20,910 shares of the company’s stock valued at $226,000 after purchasing an additional 2,120 shares in the last quarter. WINTON GROUP Ltd increased its stake in shares of Allogene Therapeutics by 6.4% during the first quarter. WINTON GROUP Ltd now owns 37,255 shares of the company’s stock valued at $184,000 after purchasing an additional 2,251 shares in the last quarter. Finally, The Manufacturers Life Insurance Company increased its stake in shares of Allogene Therapeutics by 1.2% during the second quarter. The Manufacturers Life Insurance Company now owns 203,865 shares of the company’s stock valued at $1,013,000 after purchasing an additional 2,459 shares in the last quarter. Institutional investors own 78.51% of the company’s stock.

Allogene Therapeutics Stock Up 1.4 %

Allogene Therapeutics stock opened at $2.99 on Tuesday. The company has a market capitalization of $503.15 million, a PE ratio of -1.33 and a beta of 0.83. The firm has a fifty day simple moving average of $3.14 and a two-hundred day simple moving average of $4.35. Allogene Therapeutics has a twelve month low of $2.31 and a twelve month high of $11.10.

Allogene Therapeutics Company Profile

Allogene Therapeutics, Inc, a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell ALL.